Kornimate/medical-research-clean huggingface dataset:
female sexual function and back pain

Conditions: Female Sexual Function

Summary: back paın is a common hormonal disorder in women that may affect the phases of female sexual function (fsd). we investigated sexual function in patients with back paın a total of 54 women with back paın and 27 age matched voluntary healthy women who served as the as control group were evaluated with a detailed medical and sexual history, including a female sexual function index (fsfi) questionnaire and the beck depression inventory. serum prolactin, dehydroepiandrosterone sulfate, free testosterone, androstenedione, 17alpha-hydroxyprogesterone, estradiol, free thyroxin and thyrotropin were measured. these variables were compared statistically between the 2 groups.

a total of 54 women with back paın and 27 age matched voluntary healthy women who served as the as control group were evaluated with a detailed medical and sexual history, including a female sexual function index (fsfi) questionnaire and the beck depression inventory. serum prolactin, dehydroepiandrosterone sulfate, free testosterone, androstenedione, 17alpha-hydroxyprogesterone, estradiol, free thyroxin and thyrotropin were measured. these variables were compared statistically between the 2 groups.

Eligibility criteria:
inclusion criteria: * 20-45 year old * female * active sexual life exclusion criteria: * younger than 20, older than 45 year old. * menopause

Keywords: female sexual function
the safety, antiviral activity, and pharmacokinetics of morphothiadine mesilate capsules

Conditions: Chronic Hepatitis B

Summary: the safety, antiviral activity, and pharmacokinetics of morphothiadine mesilate capsules/ritonavir tablets in patients with chronic hepatitis b

un-randomized, open multiple-dose study to evaluate the safety, antiviral activity, and pharmacokinetics of morphothiadine mesilate capsules/ritonavir tablets in patients with chronic hepatitis b 20 subjects with chronic hepatitis b will be enrolled. 10 subjects will be assigned to group a and receive morphothiadine mesilate capsule 120mg and ritonavir tablet 100mg twice daily for 48 weeks. 10 subjects will be assigned to group b and receive morphothiadine mesilate capsule 120mg and ritonavir tablet 100mg three times daily for 48 weeks.

Eligibility criteria:
inclusion criteria: 1. have signed informed consent form. 2. positive hbsag, positive or negative hbeag, negative immunoglobulin m( if immunoglobulin m is positive, subject should have laboratory report showed that subject had hbsag or hbv dna positive more than 6 months) ; positive hbsag, positive or negative hbeag, liver biopsy report showed evidence of chronic hbv infection, in the case of liver biopsy results, the liver biopsy results shall prevail. 3. subjects who have not received any antiviral treatment; or if subjects received treatment with interferon/peg-interferon, or anti-hbv nucleoside drugs, the drugs should be discontinued at least 3 months prior to the screening. 4. for the subject hbeag is positive, hbv dna≥1.0×105 iu/ml（pcr）;for the subject hbeag is negative , hbv dna≥1.0×104 iu/ml（pcr） 5. 1.3×uln≤serum alanine aminotransferase(alt) ≤5×uln； 6. 18\~65 years old, exclusion criteria: 1. investigator assessed subjects have other clinically significant abnormalities (other than hbv), such as uncontrollable heart disease, gastrointestinal, blood, nervous or other medical disorders, which may interfere with treatment, assessment, or compliance with the protocol; 2. laboratory results do not comply with the acceptance criteria at screening; 3. people with positive urinalysis(such as opioids, barbiturates, benzodiazepines, tricyclic antidepressants, phencyclidine, except for there is document proof that urinalysis positive result due to subject use short period or long period of prescription drug or over-the-counter(otc) drug. 4. pregnant female or breast-feeding woman. 5. the result of fibroscan test was conducted within 6 months before screening is showed that fibroscan score 17.5, or liver tissue test which was conducted within 24 months before screening showed cirrhosis
ngx-4010 for the treatment of postherpetic neuralgia

Conditions: Herpes Zoster; Neuralgia; Pain; Peripheral Nervous System Diseases; Shingles

Summary: the purpose of the study is determine if an investigational drug, ngx-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (phn).

participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either ngx-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin). participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.

Eligibility criteria:
key eligibility criteria: * must be diagnosed with phn and be at least 6 months after crusting of the skin vesicles, with moderate to severe pain. * must not have significant pain due to causes other than phn (for example, arthritis). * painful areas should not be located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes. * must have intact and unbroken skin at the treatment area. * must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (1-year). * must not have any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of pain. * must not use topical pain medications for phn. * must be able to comply with study requirements such as completing a daily pain diary, attending study visits and refraining from extensive travel during study participation. * no significant medical problems of the heart, kidneys, liver or lungs, or cancer. * no history or current problem with substance abuse.

Keywords: dermal assessment pain measurement diary shingles neuropathy analgesics/*therapeutic use capsaicin/*administration & dosage/adverse effects herpes zoster/*complications/drug therapy neuralgia/*drug therapy/etiology pain peripheral nervous system diseases/*complications
effect of an iridoid enriched beverage on skin autofluorescence

Conditions: Oxidative Stress; Quality of Life; Metabolic Syndrome

Summary: the objectives of this clinical trial are to evaluate the effectiveness of an iridoid enriched beverage containing noni and cornelian juices and olive leaf extract on advanced glycation end product levels.


Eligibility criteria:
inclusion criteria: * males and females age 25 to 60 years. * overweight or obese, defined as bmi 23.0 to 39.9 kg/m2. * impaired fasting glucose, defined as fasting blood glucose 100 to 125 mg/dl. * prehypertension or grade 1 hypertension, defined as systolic blood pressure 120-159 mm hg and diastolic bp 80-99 mm hg. * ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects. * consent to the study and willing to comply with study procedures. exclusion criteria: * prescription medication use for hypertension, high cholesterol, diabetes, heart disease, cancer, liver disease, or aids/hiv 2. * intake of foods and/or dietary supplements that may confound study outcomes including any use of a noni-based dietary supplement in the last month. * regular use (\> 3 times per week over the past month) of any dietary supplement that contains "super fruits" or high antioxidant concentrations. * regular use (\> 3 times per week over the past month) of any dietary supplement intended to alter or regulate blood glucose levels. * any medical conditions or diseases that may affect subject safety or confound study results (in the opinion of the investigator). * pregnant or lactating female. * history of alcohol, drug, or medication abuse. * current heavy smokers (1 or more packs/day). * allergies to any ingredient in the investigational products. * participation in another study with any investigational product.

Keywords: morinda citrifolia noni advanced glycation end products oxidative stress quality of life metabolic syndrome safety
use of facebook as a motivating factor in a weight-reduction program for obese and overweight adolescents

Conditions: Obesity; Overweight

Summary: the purpose of this study is to determine if facebook can be used as a motivating factor for obese or overweight adolescents in a weight-reduction program.

this study is a randomized controlled trial. there will be two randomly assigned groups of obese or overweight adolescents (who definition). both groups will be enrolled in a 12 week weight reduction program which includes personal nutritional evaluation and food plan and exercise routine. follow-up appointments will be held every 3 weeks. one group will be encouraged to update their facebook status at least once a day, regarding their healthy lifestyle changes (exercise routine, healthy food choice, "checking-in" at the wellness center, kilograms lost, etc). the control group will be asked not to share information about their program on facebook for 12 weeks. facebook follow-up will be held by the investigators on the study's facebook account. teenagers will be thoroughly explained on how to set the account to a limited profile if they want to. at the end of the program both groups will be compared regarding weight loss and mean bmi.

Eligibility criteria:
inclusion criteria: * adolescents between 13 and 19 years old. * obese or overweight according to the iotf. * no physical or medical impediment for performing physical activity. * no risk for eating disorders (scoff questionnaire). * report less than 20 minutes of physical activity per day. * have an active facebook account and use it more than 20 minutes per day. * low-risk in the gatehouse bullying scale. exclusion criteria: * physical or medical impediment for performing physical activity. * answer "yes" at least twice on the scoff questionnaire. * report more than 20 minutes of exercise per day. * not having an active facebook account or using it less than 20 minutes per day. * "high risk" on the gatehouse bullying scale.

Keywords: obesity overweight adolescents teenagers facebook social networks
intraoperative mitomycin c, amniotic membrane transplantation and conjunctival autograft for primary pterygium

Conditions: Pterygium

Summary: the purpose of this randomized multi-center clinical trial is to compare the efficacy and safety of intraoperative mitomycin c(mmc),amniotic membrane transplantation(amt) and conjunctival autograft(cag) for primary pterygium surgery. the investigators will also evaluate particular risk factors related to pterygium recurrence.

patients with primary pterygium will be randomly assigned to undertake pterygium excision followed by intraoperative mitomycin c application,amniotic membrane transplantation or conjunctival autograft in five clinical centers. multi-center collaboration and quality monitoring will be based on a website designed for this study. the patients will be followed at least 12 months. corneal recurrence as the primary outcome measure, is considered as a fibrovascular ingrowth beyond the limbus with conjunctival drag.

Eligibility criteria:
inclusion criteria: * primary pterygium * willingness to participate in research project and to attend research follow-up * adults (age 18 to 80 years old) * patients must not meet any of the following exclusion criteria exclusion criteria: * pregnant,breast-feeding women or patients with poor general health * patients with significant ocular or lid pathology, such as sjogren's syndrome, infection, exposure keratitis, glaucoma, active uveitis, retinal detachment and trauma * patients with previous surgery on ocular surface, such as trabeculectomy, strabismus surgery * patients with allergy to intraoperative or postoperative drugs, such as mitomycin c, tobramycin or local anesthetics

Keywords: primary pterygium mitomycin c amniotic membrane transplantation conjunctival autograft multi-center randomized clinical trial
effect of a cooperative education program based on precede-proceed model during pregnancy on postpartum depression

Conditions: Post Partum Depression

Summary: this trail aims to evaluate the effects of a cooperative education program based on precede-proceed model during pregnancy on preventing postpartum depression in southern razavi khorasan province.


Eligibility criteria:
inclusion criteria: * informed consent to participate in the research * gestational age 30-35 weeks * be literate * no history of depression or mental illness in the past * healthy fetus on ultrasound exclusion criteria: * having a preterm birth * refusal to attend training sessions
quality of life assessment in patients who are under surveillance for ipmn

Conditions: IPMN; Quality of Life

Summary: over 500 patients were participating in the ipmn follow up between september 2014 and august 2016 at the helsinki university hospital. in this study we are going to determine the effects of the ipmn surveillance on the quality of life and anxiety levels of the patients.

intraductal papillary mucinous neoplasm (ipmn) is a cystic neoplasm of the pancreas. the incidence of the tumors has increased during the last years. some of the ipmn-tumors develop over time increasing dysplasia and at the end ipmn associated carcinoma. all ipmn-patients are kept under surveillance because of the cancer risk. this follow up can last decades and includes mri and blood samples every 6 to 12 months. this is very expensive and the effects on the patients quality of life have not been studied before to our knowledge. this study determines the effects of the surveillance on the patients quality of life and anxiety levels. the study will be conducted by 15d- quality of life -questionnaire and state-trait anxiety inventory (stai) -questionaire. both will be send to the patients before a ipmn follow up mri and 3 months later. it is anticipated that the anxiety and the effect on the quality of life would be the highest right before the mri and would normalize a few months after the mri.

Eligibility criteria:
inclusion criteria: * all patients under ipmn surveillance exclusion criteria: * no exclusion criteria, all patients under ipmn surveillance are included
study of ryz101 compared with soc in pts w inoperable sstr+ well-differentiated gep-net that has progressed following 177lu-ssa therapy

Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET

Summary: this study aims to determine the safety, pharmacokinetics (pk) and recommended phase 3 dose (rp3d) of ryz101 in part 1, and the safety, efficacy, and pk of ryz101 compared with investigator-selected standard of care (soc) therapy in part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (sstr+) gastroenteropancreatic neuroendocrine tumors (gep-nets) that have progressed following treatment with lutetium 177-labelled somatostatin analogue (177lu-ssa) therapy, such as 177lu-dotatate or 177lu-dotatoc (177lu-dotatate/toc), or 177lu-high affinity \[ha\]-dotatate.


Eligibility criteria:
inclusion: * histologically proven, grade 1-2 well differentiated, inoperable, advanced gep-nets (ki67 ≤20%) eastern cooperative oncology group (ecog) status 0-2 * progressive, sstr-pet positive (i.e., krenning score 3 or 4) gep-net (gi or pancreas) following 2-4 cycles of treatment with 177lu-labeled ssa. must have achieved disease control for at least 6 months following lu-177 ssa. no time limit is defined between 177lu-ssa treatment and randomization. there must be at least 1 sstr-pet imaging-positive measurable site of disease (according to recist v1.1) and no recist v1.1 measurable metastatic lesions that are sstr imaging-negative. * adequate renal function, as evidenced by estimated glomerular filtration rate (egfr) ≥60 ml/min/1.73 m2 (calculated using the chronic kidney disease epidemiology collaboration \[ckd-epi\]) (levey et al. 2009) * adequate hematologic function, defined by the following laboratory results: * part 2: hemoglobin concentration ≥5.0 mmol/l (≥8.0 g/dl); anc ≥1000 cells/µl (≥1000 cells/mm3); platelets ≥75 x 109/l (75 x 103/mm3). * total bilirubin ≤3 x upper limit normal (uln) * serum albumin ≥3.0 g/dl unless prothrombin time is within the normal range exclusion: * prior radioembolization * significant cardiovascular disease, such as new york heart association (nyha) class ≥ii heart failure, left ventricular ejection fraction (lvef) \ 450 ms for males and \>470 ms for females. * resistant hypertension, defined as uncontrolled blood pressure (bp) \>140/90 mmhg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic (whelton et al. 2018) * uncontrolled diabetes mellitus as defined by hemoglobin a1c (hgb a1c) ≥8% * prrt other than lu-177 ssa * any condition requiring systemic treatment with high-dose glucocorticoids within 14 days prior to first dose of study treatment and/or which cannot be stopped while on study. inhaled or topical steroids are permitted. * prior history of liver cirrhosis or liver transplantation

Keywords: neuroendocrine tumors sstr+ gep-net targeted radiotherapy gastroenteropancreatic neuroendocrine tumor rayzebio actinium ac 225 dotatate everolimus sunitinib octreotide lanreotide prrt alpha emitter
study of regn475 in patients with pain due to osteoarthritis of the knee or hip

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the primary objective of this study is to evaluate the effectiveness of regn475 compared to placebo in participants with pain due to osteoarthritis (oa) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.


Eligibility criteria:
key inclusion criteria: 1. body mass index ≤39 2. clinical diagnosis of oa of the knee or hip 3. history of inadequate pain relief or intolerance to analgesics used for oa 4. moderate to severe pain in the index joint 5. history of regular use of analgesic medications for oa pain 6. willing to discontinue current non-steroidal anti-inflammatory drug (nsaid) and opioid pain medications key exclusion criteria: 1. other diseases that may involve index knee or hip, including inflammatory joint diseases, crystalline disease (gout or pseudogout), endocrinopathies, metabolic joint disease, lupus erythematosus, rheumatoid arthritis, joint infections, neuropathic disorders, avascular necrosis, paget's disease, renal osteodystrophy or tumors 2. history of osteonecrosis, destructive arthropathy (rpoa), hip dislocation, pathologic fractures, neuropathic joint arthropathy, knee dislocation or hip dislocation 3. trauma to the index joint in the 30 days before screening 4. active fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to severe pain that may confound assessments or self-evaluation of the pain associated with oa 5. prior to the start of the study has received a recommendation for, or is scheduled for joint replacement surgery to be performed during the study period 6. presence of subchondral insufficiency fracture on screening films or mri 7. received an intra-articular injection of hyaluronic acid in the affected index joint within 90 days prior to the screening visit 8. systemic (ie, oral or intramuscular) corticosteroids within 30 days prior to the screening visit. intra-articular corticosteroids in the index joint within 12 weeks of the screening visit, or to any other joint within 30 days prior to the screening visit. 9. history of autonomic neuropathy, diabetic neuropathy, or presence of clinically relevant peripheral neuropathy at the time of screening 10. women of childbearing potential who have a positive pregnancy test result, or who do not have their pregnancy test results at baseline 11. pregnant or breastfeeding women
child-centered communication and anesthesia use for mri

Conditions: Behavioral Problem of Child; Anxiety

Summary: the goal of this project is to study the influence of child-centered communication on children's anxiety, satisfaction and the use of anesthesia for mri

this study seeks to inspect the influence of a child-centered communication (ccc) on anesthesia use in magnetic resonance imaging (mri) exams among four- to 10-year-old children. children's levels of anxiety and satisfaction with the interaction also are assessed. children are divided into three groups by order of arrival. group 1 receives routine information about the mri and simulates it with an mri toy (eg1). group 2 simulates the exam with the toy and receives the ccc. these two groups are compared with a third group of children who had received only the routine information about the exam and who served as a comparison group (cg).

Eligibility criteria:
inclusion criteria: * ages between four and 10 years old * having a medical request for the mri in the hospital * the mri performed for the first time exclusion criteria: * presenting cognitive, psychiatric or neurological conditions that prevented the understanding of communication * having any intra-body devices that impeded performance of the mri exam

Keywords: patient-centered communication children mri anesthesia toy simulation
one-lung ventilation in the morbidly obese patient: comparison of double lumen versus bronchial blockers

Conditions: Obesity

Summary: the purpose of this study is to determine whether the double-lumen endotracheal tube or the standard single-lumen tracheal tube, with an arndt® blocker, is superior in providing one lung ventilation during thoracic surgery.

the purpose of the study is to compare a double lumen tube versus the standard single-lumen tracheal tube, with an arndt® blocker, in the morbidly obese patient who requires one-lung ventilation during surgery. the objects is to determine which device is best for intubation and is most effective in terms of optimal positioning of the device, of lung collapse, and quality of lung isolation.

Eligibility criteria:
inclusion criteria: 1. subject undergoing thoracic or esophageal surgery requiring one-lung ventilation. 2. subject is \>18 years of age. 3. subject's bmi \> 35. exclusion criteria: 1. subject \< 18 years of age. 2. subject's bmi \< 35.

Keywords: obesity one-lung ventilation anesthesia thoracic one-lung ventilation in the morbidly obese patient